Introduction Non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations represents a distinct subset of cancer that presents significant treatment challenges. These mutations lead to abnormal activation of the MET receptor, promoting cancer cell growth and survival. Targeted therapies, such as tepotinib, a selective MET inhibitor, have
Case of Increased Risk of Pregnancy-associated Breast Cancer Recurrence
1004 Reached2 Comments
Treatment of Recurrent Adult Medulloblastoma
2601 Reached1 Comments4 Likes
Black Lesion in Old Female
1963 Reached5 Comments11 Likes
NSCLC Treatment To Control Long-term Tumor Growth
216 Reached1 Comments
Secondary Pseudophakic Malignant Glaucoma
1616 Reached21 Comments12 Likes